Zacks.com Quotes and Research

DENDREON CP (NASD)
DNDN 27.20 -0.34 (-1.23%) Vol.  1,476,660 16:00 ET

Day Low - High 27.08 - 27.66
52wk Low - High 2.55 - 30.42
Avg Volume 2,535,960
Industry MED-BIOMED/GENE
Market Cap 3.19 B
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -1.64
EPS Last Year -1.93
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/12/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
DENDREON CP DNDN PREMIUM
KERYX BIOPHARMA KERX PREMIUM
PROMETIC LIFE T.PLI PREMIUM
OREXIGEN THERAP OREX PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.53
ABR (Last Week) 1.53
# of Recs in ABR 15
Average Target Price 34.80
Industry Rank by ABR 49 out of 217
Rank in Industry 71 out of 172
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate DNDN?
Buy
Sell
Find out what the Zacks Community
thinks of DNDN at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR DNDN
Zacks Equity Research: Report for DNDN
Nov 12, 2009
Zacks Blog: Dendreon to Seek FDA Approval
Oct 09, 2009
Zacks Blog: Dendreon Awaits Provenge Approval
Sep 28, 2009
Zacks Blog: Wider Loss for Dendreon
Aug 17, 2009
Zacks Blog: Dendreon Raising Money
Jul 07, 2009
More Zacks Commentary
NEWS
BiomedReports: News and FDA Updates for OPTIMIZERx (OTC:OPRX), Dendreon (Nasdaq:DNDN), Ligand (NASDAQ:LGND)
Nov 23, 2009
xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 20, 2009 : DNDN, POZN, VCLK and NUAN
Nov 20, 2009
Dendreon Receives FDA Acknowledgement of Complete Response
Nov 20, 2009
BUYINS.NET: Dendreon (DNDN) Down After BUYINS.NET Report Predicted Weakness After Earnings
Nov 12, 2009
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Nov 11, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate -0.29 -0.25 -1.64 -0.59
Number of Estimates 11 2 13 13
Low Estimates -0.42 -0.29 -2.17 -0.90
High Estimate -0.20 -0.21 -0.70 -0.31
Year Ago EPS -0.17 -0.16 -0.80 -1.64
EPS Growth -67.91% -56.25% -105.29% 64.22%

More Estimates

COMPANY DESCRIPTION
Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. Through the use of antigen engineering and proprietary cell separation technologies, Dendreon develops therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer. In addition to its products for cancer, Dendreon also intends to pursue the application of its technologies in the fields of autoimmune diseases, allergies and infectious diseases.

Full Company Report
FINANCIALS
EPS TTM -1.93
Sales .11
Net Income -196.49
Price/Earnings N/A
Price/Book 26.8
Price/Cash Flow N/A
Price/Sales 29515.23


More Financials